In silico identification of 2-oxo-1,3-thiazolidine derivatives as novel inhibitor candidate of class II histone deacetylase (HDAC) in cervical cancer treatment  by Tambunan, Usman S.F. et al.
Arabian Journal of Chemistry (2015) xxx, xxx–xxxKing Saud University
Arabian Journal of Chemistry
www.ksu.edu.sa
www.sciencedirect.comORIGINAL ARTICLEIn silico identiﬁcation of 2-oxo-1,3-thiazolidine
derivatives as novel inhibitor candidate of class II
histone deacetylase (HDAC) in cervical cancer
treatment* Corresponding author.
E-mail addresses: usman@ui.ac.id (U.S.F. Tambunan), arli@daad-alumni.de (A.A. Parikesit), abi.sofyan@sci.ui.ac.id (A.S. G
chevhe@gmail.com (C.P. Satriyanto).
Peer review under responsibility of King Saud University.
Production and hosting by Elsevier
http://dx.doi.org/10.1016/j.arabjc.2015.07.010
1878-5352 ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Please cite this article in press as: Tambunan, U.S.F. et al., In silico identiﬁcation of 2-oxo-1,3-thiazolidine derivatives as novel inhibitor candidate of class I
deacetylase (HDAC) in cervical cancer treatment. Arabian Journal of Chemistry (2015), http://dx.doi.org/10.1016/j.arabjc.2015.07.010Usman S.F. Tambunan *, Arli A. Parikesit, Abi S. Ghifari, Cipta Prio SatriyantoDepartment of Chemistry, Faculty of Mathematics and Natural Science, University of Indonesia, Depok 16424, IndonesiaReceived 16 January 2014; accepted 17 July 2015KEYWORDS
HPV;
Cervical cancer;
2-Oxo-1,3-thiazolidine;
HDAC;
Inhibitors;
CADDDAbstract Cervical cancer ranks third among the most prevalent deadly cancer in women world-
wide and ranks ﬁrst in developing countries. It is caused by human papilloma virus (HPV) infection.
Thus HDACs have become prominent inhibition target for cervical cancer treatment. In order to
discover the new alternative HDAC inhibitors (HDACIs), we conducted a computer-aided drug
discovery and development (CADDD) based on de novo approach. The compound library is based
on 4-[(2-oxo-1,3-thiazolidin-3-yl)carbonyl] aniline. Screening of the best drug leads was evaluated
from several parameters, such as docking and interaction analysis, pharmacology, in silico preclin-
ical trial and molecular dynamics analysis. The inhibitory activity of these new designed ligands
against Homo sapiens class II HDAC was determined by molecular docking simulation. Docking
analysis yielded eight best ligands which have better binding afﬁnity than the standards.
Therefore, interaction analysis indicated that all best ligands performed coordination with Zn2+
cofactor in HDAC charge-relay system which are essential for HDAC inhibitory activities of these
inhibitors. Pharmacology analysis and preclinical trials of these compounds including pharmacol-
ogy properties, bioactivity, mutagenicity–carcinogenicity, absorption, distribution, metabolism,
excretion and toxicity (ADMET) properties were done through in silico methods. Through this
analysis, the best ligands meet Lipinski’s rule of ﬁve, have a better drug score than standards,
and show good bioactivities, oral bioavailability and ADMET properties. All best ligands also have
good synthetic accessibility and were proved to be new compounds that have never been synthesizedhifari),
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deacetylase (HDAC) in cervical cancer treatmbefore. Stability of HDAC–ligand complexes was also calculated through molecular dynamics
(MD) simulation. Based on this simulation, complex of the best ligands with corresponding
HDAC has a good stability based on RMSD (root mean square deviation) and interaction analysis.
The study thus reveals eight best ligands (F, Ib14, O38, Kb17, Gd40, Aa50, Gc42 and Bb38) which
have better binding afﬁnity against human class II histone deacetylase (HDAC) through molecular
docking, dynamics and interaction analysis. The best ligands were also found to have good bioac-
tivities, oral bioavailability and ADMET properties through in silico pharmacology analysis and
preclinical trial. These compounds were found to have a good synthetic accessibility; therefore they
could be synthesized for further biological and clinical test.
ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Cervical cancer ranks third as the most common deadly cancer
in women worldwide and ranks ﬁrst in the developing coun-
tries (Martin and O’Leary, 2011; Zagouri et al., 2012). In
2008, it is estimated that 529,000 cervical cancer cases were
diagnosed and 274,000 of them died (Martin and O’Leary,
2011; Zagouri et al., 2012). In Indonesia, about 100 new cases
occur in 100,000 populations and it is known that 70% of them
are in the late stage (Tambunan and Wulandari, 2010).
Approximately, 99.7% of worldwide cervical cancer cases are
caused by human papillomavirus (HPV) infection (Lin et al.,
2009; Steben and Duarte-Franco, 2007). Human papillo-
mavirus (HPV) belongs to the family of simple
Papillomaviridae virus. It is non-enveloped, has icosahedral
capsid and has genetic material in the form of double-
stranded DNA with the length around 7800–7900 base pairs
and diameter of 55 nm (Paavonen, 2007). Currently, there
are more than 120 HPV genotypes which have been identiﬁed
and classiﬁed based on their risk in generating cervical cancer;
there are low risk, probable-high risk and high-risk HPV
(Steben and Duarte-Franco, 2007). There are 12 genotypes
classiﬁed as low-risk HPV (6, 11, 40, 42, 43, 44, 54, 61, 70,
72, 81, and CP6108), three genotypes as probable-high risk
HPV (26, 53, and 66) and 15 as high risk HPV (16, 18, 31,
33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, and 82). More than
70% of cervical cancer cases in the world are caused by
HPV 16 and 18 infection, while 20% of cases are caused by
types 31, 33, 35, 45, 52, and 58 (Kanodia et al., 2008; Palmer
et al., 2009).
Till date, there is no speciﬁc treatment against HPV infec-
tion in cervical cancer. Moreover, on a more serious level, sur-
gery and physico-chemo-radiotherapy are also limited (Lin
et al., 2009; Tambunan and Wulandari, 2010). One of the
treatments currently used for cervical cancer is chemotherapy;
it inhibits the HPV activity and suppresses the growth of cer-
vical cancer cell. Cervical cancer treatment currently aims to
inhibit histone deacetylases (HDACs) (Lin et al., 2009).
HDACs (E.C 3.5.1.98) are non-redundant chromatin modify-
ing enzymes that are often over-expressed in cancer caused
by HPV oncoprotein activity, especially E6 and E7 (Szalma´s
and Ko´nya, 2009; Trottier and Burchell, 2009). HDACs play
an important role in the process of deacetylation or acetyl
group release within histone protein tails, that cause histones
to be tightly twisted with DNA, thereby inhibiting transcrip-
tion of tumor suppressor genes and causing tumors to grow
into cancer cells (Tambunan and Parikesit, 2012; Tambunan, U.S.F. et al., In silico identiﬁcation of
ent. Arabian Journal of Chemistry (20et al., 2011). Thus, HDAC inhibition has become a potential
and effective strategy for inducing growth arrest, differentia-
tion and apoptosis of cancer cells in cervical cancer therapy
(Rajak et al., 2012).
Currently, variety of compounds has been synthesized and
reported to have inhibitory activity against histone deacetylase
(HDAC) and anti-proliferation activity against human cancer
cells both from in vitro and in vivo evaluation (Fournel et al.,
2008). Although there are many classes of HDAC inhibitors
(HDACIs), the most potent discovered so far is trichostatin
A (TSA) (Nair et al., 2012) and vorinostat or suberoylanilide
hydroxamic acid (SAHA); SAHA is the most widely used
and belongs to hydroxamic acid group (Tambunan et al.,
2011). However, TSA, SAHA and other HDACIs have a clear
disadvantage since their production is costly and profound
concerns remain about their toxicity, non-speciﬁcity and side
effects (Nair et al., 2012). Hence, there is a need for the discov-
ery of alternative HDACIs.
Based on pharmacophore modeling, a good HDAC
inhibitor has at least three sides/regions: the attachment side
of the Zn2+ cofactor/HDAC active site (Zn2+ binding
group/ZBG), hydrophobic cap (CAP) and linker containing
connecting unit (CU) with electronegative groups (Mohan
et al., 2011; Rossi et al., 2011). In this study, the novel
HDAC inhibitors (HDACIs) were designed from 2-oxo-1,3-
thiazolidine as Zn2+ binding group/ZBG, para-amino benzoic
acid (PABA) as linker and acetamide as connecting unit (CU)
on hydrophobic cap (CAP) (Marek et al., 2013). Furthermore,
functional group variation of these compounds was conducted
on hydrophobic cap region and inhibition studies of each var-
ied compound were employed in silico through molecular
docking and interaction analysis.
In addition, pharmacology analysis was also done for lead
molecules which have better binding afﬁnity against HDAC
than standards (Vilar et al., 2008). This analysis includes
pharmacological properties based on Lipinski’s rule of ﬁve,
bioactivity, drug likeness and drug score (Tambunan et al.,
2012). Furthermore, in silico preclinical trials including
absorption, distribution, metabolism, excretion, and toxicity
(ADMET) test, health effect probability and maximum rec-
ommended daily dose (MRDD) prediction were also per-
formed in this study (Moroy et al., 2012; van de
Waterbeemd and Gifford, 2003). The synthetic accessibility
and novelty of the lead compounds were also predicted.
This research is expected to obtain novel potential inhibitors
of Homo sapiens class II HDAC which can be used as drugs
for cervical cancer treatment.2-oxo-1,3-thiazolidine derivatives as novel inhibitor candidate of class II histone
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2.1. HDAC sequences and structures searching
H. sapiens class II HDAC enzyme sequences searching was
done at the National Center for Biotechnology Information
(NCBI) site (http://www.ncbi.nlm.nih.gov). Sequences used
in the research were the latest sequence and were supported
by valid references. Three-dimensional structure of proteins
was derived from the Protein Data Bank (PDB) at the
Research Collaboratory for Structural Bioinformatics
(RCSB) (http://www.rcsb.org/pdb). If it is not found, the 3D
structure could be modeled by using the SWISS Model
(Biozentrum Universita¨t Basel) (http://www.swissmodel.
expasy.org). All data were stored in.pdb format of structural
enzymes. Sequence and structural data were then analyzed,
making the enzymes used in this study valid and adequately
represent the other enzyme sequences.
2.2. HDAC inhibitor (HDACI) ligands design
All ligands including standard SAHA (suberoylanilide hydrox-
amic acid), TSA (trichostatin A) and VPA (valproic acid) were
designed by using ACDLabs ChemSketch 12.0 software
(Advance Chemistry Development, Inc). The reﬁnement and
optimization of three-dimensional ligands structure were also
performed. Ligand structural data were then stored in MDL
molﬁles .mol format, so they could be used in docking simula-
tions and pharmacology analysis.
2.3. Molecular docking protocols
Initial preparation for enzymes and ligands was done before
molecular docking simulation took place. All heteroatoms
(except Zn2+ ion) and water molecules were removed from
enzyme ﬁle. Polar hydrogen atoms were then added to the
enzyme (3D-protonation) to correct oxidation and tautomeric
state of amino acid residues. This process was also done to
convert Zn0 (catalytically inactive cofactor) to Zn2+ ion (cat-
alytically active cofactor). The enzyme was also minimized
using AMBER99 force ﬁeld. Similarly, ligands were
washed/protonated and minimized with MMFF94 force ﬁeld.
Thus, enzymes and ligands were ready to undergo the
simulation.
The simulation was performed using the Molecular
Operating Environment (MOE) 2008.10 software (Chemical
Computing Group, Inc). Docking between the prepared
enzymes and ligands was done without solvent (gas phase).
The placement, rescoring and reﬁnement mode chosen after
the validation of methods were Triangle Matcher, London
dG and force ﬁeld, respectively.
2.4. Docking analysis and interaction visualization
Docking simulations generate data in a MOE database .mdb
format. Screening of ligands with better binding afﬁnity
against HDAC than the three standards was performed virtu-
ally from the lowest free energy of binding (DGbinding) value.
The best ligands then went pharmacology analysis andPlease cite this article in press as: Tambunan, U.S.F. et al., In silico identiﬁcation of
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ligand complex interactions was also conducted in two- and
three-dimensions.
2.5. Pharmacology analysis and preclinical trials
Pharmacology analysis and preclinical trial were conducted to
determine the various pharmacological properties and bioac-
tivities of the newly designed inhibitors. Pharmacology analy-
sis in this study included pharmacological properties test based
on Lipinski’s rule of ﬁve, bioactivity, drug likeness and drug
score, whereas preclinical trials included ADMET (absorption,
distribution, metabolism, excretion and toxicity) test, health-
effect probability and maximum recommended daily dose
(MRDD) prediction. These analyses were performed in silico
using a variety of software such as ACD/I-Lab, FAF Drugs-
2, LAZAR, Molinspiration, Osiris and Toxtree.
2.6. Synthetic accessibility and leads novelty prediction
Synthetic accessibility prediction is needed to assess whether
the best designed drug leads are easy to synthesize in the wet
laboratory experiment or not (Ertl and Schuffenhauer, 2009).
This prediction may use CAESA (SimBioSys, Inc) software.
The novelty of lead compounds was predicted on
ChemSpider (http://www.chemspider.com) and ZINC com-
pound database (http://zinc.docking.org).
2.7. Molecular dynamics simulation
Molecular dynamics (MD) simulation was performed to assess
the stability of the enzyme HDAC with the best drug leads
complexes. First, the complex system energy was minimized
before MD simulation took place. AMBER99 force ﬁeld and
Generalized Born implicit solvation (GBIS) model were used
for this. Initialization time was determined by 100 picoseconds
(ps) dynamics at 300 K. The stability of the complex was deter-
mined by 5000 ps simulations after it was heated up to 310 K
(temperature of normal human body/cervical cancer patients)
for 20,000 ps. The simulation was ended with cooling/anneal-
ing stage to 1 K for 10 ps to obtain complex conformational
structure which has the lowest energy. The Ramachandran
plot of the most optimized ligand will be elucidated for deter-
mining the integrity of the protein structure.
3. Results and discussion
3.1. Determination of class II HDAC three-dimensional
structure
Sequences search for the six H. sapiens class II HDAC
(HDAC4, 5, 6, 7, 9, and 10) at the NCBI site produced a total
of 65 types of enzymes and their isoforms. From those differ-
ent HDAC enzyme sequences, one would be selected as a tar-
get in molecular docking simulation. Selection of enzyme
sequences is based on several parameters such as the length
of the corresponding sequence, the use of enzyme sequences
in various studies (citation number) and sequences novelty
level (newest sequences are the most valid for use). Based on2-oxo-1,3-thiazolidine derivatives as novel inhibitor candidate of class II histone
15), http://dx.doi.org/10.1016/j.arabjc.2015.07.010
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obtained from UniProt Knowledge Base (UniProtKB)/
SWISS-Prot database. The accession numbers of H. sapiens
class II HDAC sequences used as targets are P56524.3
(HDAC4), Q9UQL6.2 (HDAC5), Q9UBN7.2 (HDAC6),
Q8WUI4.2 (HDAC7), Q9UKV0.2 (HDAC9) and Q969S8.1
(HDAC10). Moreover, three-dimensional structure and crystal
data of the HDACs could be searched and obtained from its
accession code at the RCSB-PDB database. PDB IDs obtained
are 2VQJ (HDAC4: P56524.3), 3PHD (HDAC6: Q9UBN7.2)
and 3C0Y (HDAC7: Q8WUI4.2). The HDAC crystal struc-
tures were downloaded in .pdb format. Three other enzymes
(HDAC5, HDAC9, and HDAC10) 3D structures were not
obtained from PDB and needed to be modeled ﬁrst. Three-
dimensional structures modeling of proteins from their amino
acid sequences in FASTA format could be done by using
SWISS Model software (Arnold et al., 2006). Modeled enzyme
structures were then stored in .pdb format to be applied in
the MOE software for simulation. As a result of structureFigure 1 The representative structure of HDACs catalytic area. (a
Q9UQL6]. (c) HDAC6 [PDB: 3PHD]. (d) HDAC7 [PDB: 3C0Y].
[UniProtKB/SWISS-Prot: Q969S8].
Please cite this article in press as: Tambunan, U.S.F. et al., In silico identiﬁcation of
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area is seen in Fig. 1.
In addition, for analytical purpose, it was necessary that the
validity of the HDAC three-dimensional structures from
SWISS Model be veriﬁed ﬁrst; hence it was valid to employ
it in the simulation. The structure validity could be determined
from the QMEAN4 score and QMEAN Z-score values
(Benkert et al., 2011). QMEAN4 score is based on the energy
contribution to the protein structure. On the other hand,
QMEAN Z-score is based on the structure comparison
between modeled structures and experimental structures which
use high resolution X-ray crystallography that was obtained
from database. Modeled structures are valid to use if the
QMEAN4 score value is between 0 and 1. They are also valid
if QMEAN Z-score value is between 1 and 0, which indicates
the best structure. Meanwhile, the value between 2 to 1 is
acceptable, but if it is less than 3, the structure needs to be
corrected. QMEAN4 scores for HDAC5, 9, and 10 are
0.622, 0.680, and 0.577 respectively. Based on QMEAN4) HDAC4 [PDB: 2VQJ]. (b) HDAC5 [UniProtKB/SWISS-Prot:
(e) HDAC9 [UniProtKB/SWISS-Prot: Q9UKV0]. (f) HDAC10
2-oxo-1,3-thiazolidine derivatives as novel inhibitor candidate of class II histone
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Despite having a valid QMEAN4 score, HDAC10 modeled
structure is less valid based on QMEAN Z-score with a value
of 3.22. However, the structure still could be used because it
has a good structural energy based on QMEAN4 score and the
absence of protein structural data that is quite similar to
HDAC10 in protein database.
3.2. HDAC multiple sequence alignment (MSA) and residue
conservation
Multiple sequence alignment (MSA) was performed by using
the Basic Local Alignment Search Tool (BLAST). It could
be performed through the NCBI BLAST server (http://blast.
ncbi.nlm.nih.gov/Blast.cgi). Based on the MSA results, the
entire class II human HDAC enzymes belong to the HDAC
arginase superfamily (Bottomley et al., 2008; Schuetz et al.,
2008), except HDAC6 that belongs to the zinc-ﬁnger ubiquitin
binding protein (ZnF-UBP) (Ouyang et al., 2012). According
to these results, each enzyme sequence selected for docking
simulation was able to represent corresponding sequences of
the other enzymes. It could be inferred that similarity percent-
age between corresponding HDAC sequences and structures
was also high, which varied between 99% and 100%.
Therefore, the selection of sequences of enzymes used in dock-
ing simulations in this study was valid.
Furthermore, residue conservation was also conducted to
analyze the conserved residue between class II HDAC. It could
be performed by using Clustal-Omega at the EMBL-EBI
server (http://www.ebi.ac.uk/Tools/msa/clustalo/). The results
of HDAC residues conservation are shown in Fig. 2 which
shows highly conserved residues between each H. sapiens class
II HDAC.Figure 2 Residue conservation of Homo sapiens class II HDAC. Th
indicates a conserved substitution; a dot (.) indicates a semi-conserved
Please cite this article in press as: Tambunan, U.S.F. et al., In silico identiﬁcation of
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HDAC active site is needed to be determined ﬁrst to begin the
molecular docking simulation. For HDAC structures that are
derived from PDB (HDAC4, HDAC6, and HDAC7), active
residues could be known directly. Meanwhile, for the HDAC
structures that are derived from the SWISS Model, active resi-
dues could be identiﬁed by interaction analysis between
enzyme and inhibitor ligand from LigX interaction feature
on MOE (Molecular Operating Environment) according to
the template and site ﬁnder.
Generally, HDACs have two regions that are functionally
important which are carboxy/C-terminal and conserved cat-
alytic region of amino/N-terminal extension that have no sim-
ilarity with the other proteins (Schuetz et al., 2008). All
HDACs, except class III HDAC are zinc-dependent which
needs Zn2+ ion as a cofactor. The class II HDAC active site
forms a cylindrical/tubular cavity with Zn2+ ion cofactor at
the bottom of the active site. In class II HDAC, a Zn2+ cofac-
tor binds to charge-relay system that consists of two aspartate
residues (Asp/D) and one histidine residue (His/H), except
HDAC6 where the two aspartate residues are replaced by
two cysteine residues (Cys/C). For example, visualization of
cavity and charge-relay system position in HDAC5 is seen in
Fig. 3. Based on LigX interactions analysis, charge-relay sys-
tems of each H. sapiens class II HDAC are seen in Table 1.3.4. HDAC inhibitor (HDACI) ligands design
In this study, HDAC inhibitors were designed by de novo
approach from various pharmacophore fragments which are
shown to have a good inhibitory activity against HDACs.e asterisk (*) indicates identical or conserved residues; a colon (:)
substitution.
2-oxo-1,3-thiazolidine derivatives as novel inhibitor candidate of class II histone
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Figure 3 Catalytic site cavity and charge-relay system position in HDAC5. (a) Surface representation of HDAC5. Its catalytic site cavity
is shown in yellow circle. (b) Charge-relay system in HDAC5 active site which consists of a Zn2+ cofactor bound to two aspartate (Asp)
residues and one histidine (His) residue.
Table 1 Charge-relay system position in HDAC catalytic site.
Enzyme Charge-relay system position
HDAC4 Zn2+ ion, with Asp196, His198, and Asp290 residues
HDAC5 Zn2+ ion, with Asp870, His872, and Asp964 residues
HDAC6 Zn2+ ion, with Cys5, His7, and Cys78 residues
HDAC7 Zn2+ ion, with Asp707, His709, and Asp801 residues
HDAC9 Zn2+ ion, with Asp820, His822, and Asp914 residues
HDAC10 Zn2+ ion, with Asp172, His174, and Asp265 residues
6 U.S.F. Tambunan et al.De novo drug design is an approach where the structure of a
chemical compound is formed from atoms or fragments corre-
sponding to the protein target binding sites (Jain et al., 2011).
Pharmacophore model for HDAC inhibitors consists of three
main parts: zinc binding group (ZBG), linker and hydrophobic
cap (CAP). The role of ZBG is to bind Zn2+ cofactor at
enzyme active site that directly inhibits enzymatic activity.
Linker domain resembles the substrate and is able to bind
the cylindrical pocket of the HDAC active site. Meanwhile,
CAP interacts with the surface and closes the cylindrical
pocket of the HDAC active site. From this model, the com-
pound series based on 4-[(2-oxo-1,3-thiazolidin-3-yl)carbonyl]
aniline has been designed and modiﬁed to obtain the best drug
leads for cervical cancer.
In this research, 2-oxo-1,3-thiazolidine fragment was
selected for ZBG. It is a bioisosterical form of 1,3-
thiazolidine-2,4-dione which has been shown to have good
inhibitory activity against HDAC Zn2+ cofactor in liver can-
cer cell lines (Mohan et al., 2011). As a linker, para-
aminobenzoic acid (PABA) was chosen as it has been shown
to have strong interaction with hydrophobic residues on
HDAC cylindrical pocket. Its modiﬁed compounds also
appeared to have a good inhibitory activity against HDACs
both in vitro and in vivo evaluation (Rajak et al., 2012). Then
as a hydrophobic cap (CAP), acetamide group was chosen as
connecting unit (CU) and a hydrophobic group –R that may
interact with the HDAC cavity surface (Rajak et al., 2012).
The general structure of the class II HDAC inhibitor in this
study is seen in Fig. 4.Please cite this article in press as: Tambunan, U.S.F. et al., In silico identiﬁcation of
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group on hydrophobic cap. Hydrophobic –R group substitutes
include cyclohexane, cyclopentane, naphthalene, pyridine, pyr-
role, furan, thiophene, pyrimidine, imidazole, oxazole, thia-
zole, triazole, quinoline, indole and polysubstituted benzene.
In addition to these fragments, hydrophobic cap also varied
by other groups such as halides, alkyl, aryl, hydroxyl, amine,
ether and carbonyl. This design is expected to increase the
hydrophobicity and binding afﬁnity between ligand inhibitors
with class II HDAC in human. As a result, HDAC inhibitor
modiﬁcations yielded a total of 2688 ligands.
3.5. Docking analysis and virtual screening
Database containing free energy of binding of the complex
from molecular docking simulation was screened based on
the lowest DGbinding value. Most of the designed ligands have
lower DGbinding value than SAHA, TSA, and VPA standards.
But only eight best ligands were chosen as novel potential
HDAC inhibitors. They were ligand Aa50 (–R =
2-propanoyl phenyl), Bb38 (–R = 3-carboxy cyclohexyl),
F (–R= pyridin-2-yl), Gc42 (–R= 5-(hydroxyamino)-1H-pyrrol-
2-yl]), Gd40 (–R = 3-(hydroxycarboxamide)-1H-pyrrol-2-yl),
Ib14 (–R = 4-methoxythiophen-2-yl), Kb17 (–R = 5-acetyl-
1H-imidazol-2-yl) and O38 (–R = 5-carboxyl-1,2,3-
oxadiazol-4-yl). The structures of standards and eight best
ligands are shown in Fig. 5. The best designed ligands free
energy of binding calculation with corresponding class II
HDAC results are shown in Table 2. For example, one of
the best ligand that has strong interaction is Ib14 with
HDAC5 (visualized in Fig. 6).
Fig. 5(e) shows that the interaction between the ligands
with enzyme followed the hypothesis. Carbonyl (C‚O) group
of the 2-oxo-1,3-thiazolidine fragment acted as ZBG that
strongly interacts with Zn2+ cofactor on the charge-relay sys-
tem (Asp870, His872, and Asp964) and reaches 100.0% inter-
action (data in Table 8). This was also the case with the other
best ligands. Methoxythiophene fragment acted as a
hydrophobic cap and interacted with Gly962 residue on
HDAC cavity surface. PABA as a linker was also contributed2-oxo-1,3-thiazolidine derivatives as novel inhibitor candidate of class II histone
15), http://dx.doi.org/10.1016/j.arabjc.2015.07.010
Figure 4 The general structure of designed HDAC inhibitors.
In silico identiﬁcation of 2-oxo-1,3-thiazolidine derivatives 7to bind HDAC cylindrical pocket. Similar interactions were
also shown by the other best ligands.
3.6. Pharmacology analysis
Initial pharmacology analysis in this study was pharmacolog-
ical properties testing based on Lipinski’s rule of ﬁve.
Lipinski’s rule of ﬁve is quite a good approach for drug lead
design, especially in the hydrophobicity and oral bioavailabil-
ity prediction (Morya et al., 2012; Oprea, 2002). This rule is
based on the approach that the human body contains about
90% of water. Drug molecules should be hydrophobic enough
to last longer in the body and not easily excreted, as this will
enhance its bioactivity efﬁciency in the body. Modiﬁed
Lipinski’s rule of ﬁve consists of the following: molecular
weight (MW) is from 160 to 500 Da, octanol–water partition
coefﬁcient (logP) is between 0.4 and +5.6, molar refractivity
is from 40 to 130 cm3, hydrogen donor is less than 5 atoms,
hydrogen acceptor is less than 10 atoms, and topological polar
surface area (TPSA) is not more than 140 A˚2 (Ekman et al.,
2005). These pharmacological properties of standards
(SAHA, TSA, and VPA) and designed ligands could be
tested by using Molinspiration and Osiris online software
(Table 3).
As seen in Table 3, all best ligands meet the Lipinski’s rule
of ﬁve, except O38 ligand which has insigniﬁcant violations in
TPSA and numbers of hydrogen acceptor. Despite having vio-
lations, O38 ligand could still be used as potential HDAC inhi-
bitor for having a better drug likeness and drug score than
standards. We also see that all best ligands have a lower solu-
bility in water than the three standards. This result indicated
that all best ligands have a good hydrophobicity, will be able
to circulate longer and are not easily excreted out from the
body in order to enhance their activities and interactions with
target.
One of the pharmacology parameters that were also ana-
lyzed in this study is drug likeness. The drug likeness is a phar-
macological parameter that indicates fragments and
bioactivity similarity between designed ligands and already
known drugs (Hartenfeller et al., 2012). The larger value
means the higher similarity and probability that the particular
molecule will be active. The drug likeness score is calculatedPlease cite this article in press as: Tambunan, U.S.F. et al., In silico identiﬁcation of
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ilarity such as GPCR (G-protein coupled receptor) ligand, ion
channel modulator, kinase inhibitor, nuclear receptor ligand,
protease inhibitor and enzyme inhibitor properties (Kubinyi,
2006). From Table 3, it is shown that all best ligands have a
larger drug likeness value than standards, except Bb38 ligand
which has a little lower drug likeness value than TSA stan-
dards. We may conclude from this result that all best designed
ligands have high fragments and bioactivity similarity with
existing drugs.
Meanwhile, the drug score is a combination of several phar-
macological parameters such as logP (octanol–water partition
coefﬁcient), solubility, drug likeness, and toxicity parameters
prediction (mutagenicity, tumorigenicity, irritant, and repro-
ductive effect) within one useful practical value (Singh and
Tomar, 2011). The higher drug score value means that the
compounds have a better chance to be developed as drug leads.
Table 3 shows that all eight best ligands have a better drug
score than the standards and could be developed as novel
drugs for cervical cancer treatment.
3.7. In silico preclinical trial
The earliest in silico preclinical trial of the designed inhibitor
ligands in this study is toxicity prediction. Two applications
were used in this study to predict the toxicological properties
of the lead compounds such as mutagenicity and carcinogenic-
ity. They are Toxtree v2.1.0 and LAZAR which have several
differences to determine the toxicological properties of the
ligands.
Toxtree determined the toxicological properties based on
Benigni–Bossa rules. This rule could evaluate compound toxi-
city based on certain functional groups or chemical fragments
that may induce mutagenicity or carcinogenicity (Benigni
et al., 2008, 2007). The results of ligands toxicity prediction
by using Toxtree are seen in Table 4. From the results, we
could conclude that TSA standards and Gc42 ligand have
potential to be genotoxic, carcinogenic and Bb38 ligand has
potential to be mutagenic to Salmonella typhimurium TA100.
Gd40, F, Kb17, Aa50, O38 and Ib14 ligands are in accordance
with Benigni–Bossa rules because they do not have any ten-
dency to become mutagenic or carcinogenic.2-oxo-1,3-thiazolidine derivatives as novel inhibitor candidate of class II histone
15), http://dx.doi.org/10.1016/j.arabjc.2015.07.010
Figure 5 The chemical structures of the standards and the best ligands. (a) SAHA, (b) TSA, (c) VPA, (d) Aa50, (e) Bb38, (f) F, (g) Gc42,
(h) Gd40, (i) Ib14, (j) Kb17, (k) O38.
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Table 2 Free energy of binding calculation of the best ligands with corresponding HDACa.
Ligand Gibbs free energy of binding, DGbinding (kcal/mol)
HDAC4 HDAC5 HDAC6 HDAC7 HDAC9 HDAC10
SAHA 5.8131 12.2155 23.4231 6.3467 9.6285 8.2174
TSA 11.0343 7.7395 22.1517 6.9128 7.7594 9.4841
VPA 7.9939 13.5089 28.5147 6.5775 17.9370 1.0557
Aa50 11.5372 13.3201 20.9017 14.6737 9.1748 13.9624
Bb38 8.8182 14.7906 35.7428 9.2168 27.3834 7.6069
F 18.4812 9.8521 22.8164 6.5852 6.3970 9.4943
Gc42 20.2563 12.4177 20.7936 8.4926 8.5369 10.2846
Gd40 9.2588 7.9550 23.9998 7.3624 29.1305 9.2218
Ib14 18.1408 18.1124 19.5423 7.8312 13.3199 13.4759
Kb17 10.2072 12.6084 22.9797 15.1957 11.3457 9.4706
O38 12.2219 17.7518 31.0753 11.0377 25.6119 10.9574
a Numbers in bold are the lowest value of free energy of binding (DGbinding).
Figure 6 Ligand Ib14 binding to HDAC5. (a) Electron density map of the Ib14 ligand (green mesh). (b) Electron density corresponding
to the Ib14 ligand that is shown as sticks (N-(4-methoxythiophen-2-yl)-2-({4-[(2-oxo-1,3-thiazolidin-3-yl)carbonyl] phenyl}amino)
acetamide). (c) Surface representation of the HDAC5–Ib14 ligand complex. The active site/cavity of HDAC5 is indicated by a dashed
yellow circle. (d) Ib14 ligand (shown as sticks) entering the HDAC5 cavity (indicated by a dashed yellow circle) in 12 A˚ sphere. (e) Three-
dimensional visualization of detailed interaction of Ib14 (green sticks) with HDAC5 (ribbon). Side chains from HDAC5 that make contact
with Ib14 are labeled and gray colored. Hydrogen bond and electrostatic interaction are indicated by dashed lines.
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Table 3 Pharmacological properties test of standards and designed ligands using Molinspiration and Osirisa.
Ligand Molecular descriptor
MW LogP TPSA n atoms n ON n OHNH n viol n rotb Sol DrugL DrugS
SAHA 264.325 2.467 78.424 19.0 5 3 0 8 -3.33 -8.87 0.35
TSA 302.374 2.683 69.635 22.0 5 2 0 6 -3.26 1.24 0.37
VPA 144.214 2.804 37.299 10.0 2 1 0 5 -1.97 -2.62 0.3
Aa50 411.483 2.538 95.576 29.0 7 2 0 7 -4.72 3.24 0.39
Bb38 405.476 1.403 115.804 28.0 8 3 0 6 -3.46 0.98 0.41
F 356.407 1.285 91.397 25.0 7 2 0 5 -3.49 4.44 0.49
Gc42 484.319 2.443 94.296 26.0 7 3 0 6 -3.55 3.69 0.48
Gd40 403.42 0.625 132.765 28.0 10 4 0 5 -3.89 3.82 0.46
Ib14 391.474 1.953 87.739 26.0 7 2 0 6 -3.83 3.8 0.46
Kb17 403.42 0.762 133.493 28.0 10 3 0 7 -3.67 3.66 0.46
O38 391.365 0.071 154.728 27.0 11 3 1 6 -3.41 3.71 0.48
a MW=molecular weight in Da; logP= octanol–water partition coefﬁcient; TPSA= topological polar surface area in A˚2; n ON= number
of hydrogen acceptor atoms (oxygen and nitrogen); n OHNH= number of hydrogen donor atoms; n viol = number of Lipinski’s rule of ﬁve
violations; n rotb = number of rotatable bonds; sol = solubility; drugL = drug likeness; drugS = drug score. Numbers in bold are indicated
the higher drug score than standards.
Table 4 Toxicological properties prediction of standards and designed ligands using Toxtree.
Ligand Negative for genotoxic
carcinogenicity
Negative for nongenotoxic
carcinogenicity
Potential S. typhimurium TA100
mutagen
Potential
carcinogen
SAHA Yes Yes No No
TSA No Yes Yes No
VPA Yes Yes No No
Gc42 No Yes No No
Gd40 Yes Yes No No
Bb38 Yes Yes Yes No
F Yes Yes No No
Kb17 Yes Yes No No
Aa50 Yes Yes No No
O38 Yes Yes No No
Ib14 Yes Yes No No
Table 5 Toxicological properties prediction of standards and designed ligands using LAZAR.
Ligands Mutagenicity Carcinogenicity
DSS-Tox DBS Salmonella Kazius–Bursi Hamster Mouse Rat Single cell call Multiple cell call ISSCAN v3a Canc
SAHA Yes Yes No No No No No Yes
TSA No Yes No Yes No No No No
VPA No No No No No No No Yes
Gc42 Yes Yes No No No Yes No No
Gd40 Yes Yes No No No Yes No No
Bb38 No Yes No No No No No No
F Yes Yes No No No Yes No No
Kb17 Yes Yes No No No Yes No No
Aa50 No Yes No No No No No No
O38 Yes Yes No No No Yes No No
Ib14 Yes Yes No No No Yes Yes No
10 U.S.F. Tambunan et al.The next toxicity prediction is using LAZAR (Lazy
Structure–Activity Relationship). This software could evaluate
toxicological properties of the ligands based on chemical frag-
ments similarity with already known toxic fragments from
compounds database (Maunz and Helma, 2008). The resultsPlease cite this article in press as: Tambunan, U.S.F. et al., In silico identiﬁcation of
deacetylase (HDAC) in cervical cancer treatment. Arabian Journal of Chemistry (20are shown in Table 5. Compounds mutagenicity was evaluated
from DSS-Tox (Distributed Structure-Searchable Toxicity)
database and S. typhimurium assay test based on Kazius–
Bursi method. From this evaluation, we may see that almost
all designed ligands have mutagenic properties based on2-oxo-1,3-thiazolidine derivatives as novel inhibitor candidate of class II histone
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Table 6 Preclinical trial of standards and designed ligands using ACD/I-Laba.
Ligand Max. passive absorption
(Trans/Para)
Health eﬀect probability Oral
bioavailability
(%)
MRDD (mg/
kg/day)
Blood Cardio
vascular
Gastro
intestinal
Kidney Liver Lungs
SAHA 100 (100/0) 0.36 0.25 0.07 0.11 0.11 0.37 >70 8.49
TSA 100 (100/0) 0.59 0.5 0.51 0.27 0.52 0.63 30–70 10.05
VPA 100 (100/0) 0.09 0.09 0.08 0.05 0.05 0.05 >70 15.46
Gc42 100 (100/0) 0.51 0.11 0.78 0.54 0.74 0.11 <30 4.55
Gd40 20 (59/41) 0.42 0.14 0.24 0.74 0.26 0.76 <30 13.33
Bb38 100 (100/0) 0.85 0.04 0.5 0.42 0.56 0.13 <30 1.51
F 100 (100/0) 0.42 0.33 0.65 0.36 0.25 0.25 30–70 4.95
Kb17 98 (99/1) 0.61 0.43 0.23 0.51 0.7 0.18 <30 4.52
Aa50 100 (100/0) 0.31 0.23 0.51 0.63 0.31 0.42 <30 6.99
O38 54 (99/1) 0.47 0 0.16 0.37 0.7 0.1 <30 11.88
Ib14 100 (100/0) 0.18 0.36 0.09 0.25 0.15 0.11 30–70 11.23
a Trans/Para represent the contribution of transcellular/paracellular pathways.
Table 7 Synthetic accessibility prediction of the best ligands
using CAESA.
Ligands Residual
complexity (%)
Starting
materials (%)
Synthetic
accessibility (%)
SAHA 3 75 93
TSA 0 100 100
VPA 0 100 100
Gc42 17 49 75
Gd40 18 46 74
Bb38 7 72 88
F 4 55 82
Kb17 16 56 77
Aa50 13 60 81
O38 19 48 74
Ib14 15 43 76
In silico identiﬁcation of 2-oxo-1,3-thiazolidine derivatives 11DSS-Tox database and S. typhimurium assay test, except Bb38
and Aa50 ligands which have no mutagenic properties based
on DSS-Tox DBS. Moreover, due to its mutagenic properties,
it does not always lead to carcinogenicity; the ligands carcino-
genic properties were also evaluated by animal assay test,
which are hamster, mouse, and rat. We can see in Table 5 that
all best ligands were not carcinogenic to those animals.
Carcinogenic properties were also calculated by using
ISSCAN (Instituto Superiore di Sanita Chemical
Carcinogens) method which is developed by Benigni and
Bossa from the Department of Environment and Primary
Prevention, United States Environmental Protection Agency
(US-EPA) (Benigni et al., 2007). From this evaluation, all best
designed ligands have no carcinogenic properties, especially as
cancer causative agents. In contrast, SAHA and VPA stan-
dards may cause cancers based on this method.
The last stage of in silico preclinical trial was ADMET test
including absorption, health effect probability, and oral
bioavailability prediction using ACD/I-Lab (Lagorce et al.,
2008; van de Waterbeemd and Gifford, 2003). Absorption pre-
diction yielded maximum passive absorption percentage from
the contribution of transcellular and paracellular routes.
Passive absorption is a process in which the molecules are
absorbed through the intestinal mucosa or epithelial cells thatPlease cite this article in press as: Tambunan, U.S.F. et al., In silico identiﬁcation of
deacetylase (HDAC) in cervical cancer treatment. Arabian Journal of Chemistry (20do not use energy or ATP contribution along the process.
Passive absorption is divided into two major sub-types based
on the route it takes: transcellular and paracellular.
In transcellular route absorption, the compounds cross the
cell membranes and enter the cell. Meanwhile, in paracellular
route, the compounds cross the tight junction between cells
(Pendekal and Tegginamat, 2013). Transcellular route was
the favored pathway for most drugs, probably due to its larger
accessible surface area. The paracellular permeability of a drug
was size- and charge-dependent, which is decreased with
increasing molecular size and negative charge (Agoram et al.,
2001).
Table 6 shows that all best ligands, except Gd40 and O38,
have a high maximum passive absorption percentage with con-
tribution only (or dominantly, for Kb17 ligand) from transcel-
lular route, the favored pathway for most drugs. We may
conclude then that all best ligands except Gd40 and O38 have
a good passive absorption, which is an essential parameter for
drug development.
Health effect probability prediction was also conducted in
this study by using ACD/I-Lab. The probability value ranges
between 0 and 1; increasing probability reached 1 (one)-
which means the compounds have a higher health effect to cor-
responding organs or organ systems. The threshold value of
health effect probability is 0.85; the probability score below
this value is still acceptable. We can see in Table 5 that all best
ligands have a low health effect probability, except Bb38
ligand which has relatively high health effect probability that
reaches threshold value on blood. On average, the ligand that
has the lowest health effect probability is Ib14. Due to its
health effect, ACD/I-Lab could also predict the maximum rec-
ommended daily dose (MRDD) if the designed ligands will be
developed as cervical cancer drugs.
Based on the hydrophobicity of the designed ligands, the
oral bioavailability could also be calculated using FAF-
Drugs2 and ACD/I-Lab software. From FAF-Drugs2 predic-
tion, all best ligands have a good oral bioavailability based on
Veber’s and Egan’s rules (Lagorce et al., 2008). The best
ligands that have the highest oral bioavailability are F and
Ib14 with oral bioavailability that ranges between 30% and
70%.2-oxo-1,3-thiazolidine derivatives as novel inhibitor candidate of class II histone
15), http://dx.doi.org/10.1016/j.arabjc.2015.07.010
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The next step in drug discovery after computer-aided drug dis-
covery and development (CADDD) is clinical test. For further
clinical trial, the best designed ligands from in silico approach
have to be synthesized ﬁrst to determine their in vitro and
in vivo bioactivity. For this reason, synthetic accessibility of
in silico designed ligands then has to be assessed to evaluate
the synthetic probability and feasibility of the ligands.
The bases of this prediction method are screening and
informational analysis of the contribution of particular frag-
ments and the complexity of the structures derived from data-
base containing millions of compounds that are already
synthesized. So from this method, the synthetic accessibilityFigure 7 RMSD curve of molecular dynamics simulation at 5000 ps
5.5 A˚, HDAC5–Ib14 at 6.5 A˚, HDAC6–O38 at 1.5 A˚, HDAC7–Kb17
Figure 8 RMSD curve of HDAC4-F molecular dynamics simulati
beginning to retain its stability.
Please cite this article in press as: Tambunan, U.S.F. et al., In silico identiﬁcation of
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thesis approach (Ertl and Schuffenhauer, 2009). Software that
could be used to predict the synthetic possibility by using this
method is CAESA (Computer Assisted Estimation of
Synthetic Accessibility). These tools can estimate the percent-
age of synthetic accessibility based on the existence of starting
materials and structural or residual complexity (Ertl and
Schuffenhauer, 2009). Synthetic accessibility prediction of the
best ligands is presented in Table 7.
TSA and VPA standards have easy synthetic accessibility
percentage that reaches 100%. It is because they have been
synthesized and already listed on Acros, Aldrich, or
Lancaster database. All best ligands have a low residual com-
plexity and a high synthetic accessibility. Based on this result,. All complex are stable in respective RMSD value: HDAC4–F at
at 5.0 A˚, HDAC9–Gd40 at 7.5 A˚, and HDAC10–Aa50 at 8.5 A˚.
on at 20,000 ps. It is shown that after 4000 ps, the simulation is
2-oxo-1,3-thiazolidine derivatives as novel inhibitor candidate of class II histone
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that have been synthesized and registered in the database.
All designed inhibitor ligands are predicted to be com-
pounds that have never been synthesized before. Novelty eval-
uation could be done by searching ligand chemical structures
on ChemSpider and ZINC compounds database. Through
identical and similar structures, tautomers, structural and geo-
metrical isomers search, all designed ligands were not found on
both databases. According to this result, it could be predicted
that the designed inhibitors were new compounds and have
never been synthesized before.
3.9. Drug screening based on docking, dynamics and drug scan
analysis
The best inhibitor ligands could be determined based on
docking and drug scan analysis (pharmacology analysis and
preclinical trial). For HDAC4, HDAC5, HDAC6, HDAC7,
HDAC9 and HDAC10, the best inhibitor ligands are Gc42,
Ib14, O38, Kb17, Gd40, and Aa50 respectively due to their
lowest free energy of binding compared with other ligands.
Although Gc42 ligand is the best inhibitor for HDAC4, it is
predicted to have genotoxic carcinogenicity based on
Benigni–Bossa rules. It is also found to have a high healthFigure 9 The Ramachandran plot of HDAC4-F. The plot show
Please cite this article in press as: Tambunan, U.S.F. et al., In silico identiﬁcation of
deacetylase (HDAC) in cervical cancer treatment. Arabian Journal of Chemistry (20effect probability and low oral bioavailability. The other
ligand that also has a good binding afﬁnity to HDAC4 is F
ligand. Nevertheless, based on drug scan, F ligand does not
have any mutagenic–carcinogenic properties and has better
pharmacological properties such as health effect probability
and oral bioavailability than Gc42 ligand. Thus, F ligand
was then chosen as the best inhibitor for HDAC4.
The other best ligands (Ib14, O38, Kb17, Gd40, and Aa50
for HDAC5, HDAC6, HDAC7, HDAC9, and HDAC10
respectively) are already in accordance with Lipinski’s rule of
ﬁve; they have lowest mutagenic–carcinogenic properties, a
good passive absorption, health effect probability score and
oral bioavailability based on Veber’s and Egan’s rules.
The structure and property differences among the best
ligands of respective H. sapiens class II HDAC are a conse-
quence of characteristics differences among HDAC.
Structural and amino acid residues differences in HDAC
catalytic site cause tendency in interaction differences.
3.10. Molecular dynamics simulation
Protein does not have a ﬁxed structure because of rapid con-
formational changes in the presence of solvent. This is so
because the atoms movement in protein backbone causess that most of the residues are still within the allowed region.
2-oxo-1,3-thiazolidine derivatives as novel inhibitor candidate of class II histone
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Table 8 Interaction data of the simulationsa.
Complex The best interactions between ligand and HDAC in molecular dynamics simulation
HDAC4–F Before simulation (docking) Initialization 100 ps (300 K)
Glu329: 36.1%; H-acc; 2.58 A˚ Zn-Asp196: 41.6%; ionic; 1.80 A˚
Zn-Asp196: 90.4%; ionic; 2.30A˚ Zn-Asp196: 34.9%; ionic; 1.77 A˚
Zn-Asp196: 76.9%; ionic; 1.99 A˚ Zn2+: 100.0%; ionic; 2.70 A˚
Zn-His198: 19.7%; ionic; 1.94 A˚
Zn-Asp290: 21.4%; ionic; 1.91 A˚
Zn2+: 100.0%; ionic; 2.69 A˚
Equilibration – heating 10 ps Simulation 5000 ps – cooling 10 ps
Ser287: 24.5%; H-donor; 1.67 A˚ Leu326: 13.8%; H-donor; 1.97 A˚
Ser287: 12.2%; H-acc; 2.98 A˚ Zn-Asp196: 48.7%; ionic; 1.84 A˚
Zn-Asp196: 30.3%; ionic; 2.03 A˚ Zn-Asp196: 48.6%; ionic; 1.84 A˚
Zn-His198: 23.8%; ionic; 1.79 A˚ Zn-His198: 26.8%; ionic; 2.10 A˚
Zn2+: 100.0%; ionic; 2.15 A˚ Zn-Asp290: 56.2%; ionic; 1.88 A˚
Zn-Asp290: 42.0%; ionic; 1.81 A˚
Zn2+: 100.0%; ionic; 1.86 A˚
HDAC5–Ib14 Before simulation (docking) Initialization 100 ps (300 K)
Ser960: 29.9%; H-acc; 2.73 A˚ Zn-His872: 32.7%; ionic; 1.78 A˚
Asp964: 40.8%; H-acc; 2.80 A˚ Zn-Asp964: 62.4%; ionic; 1.92 A˚
Zn-Asp870: 93.8%; ionic; 2.10 A˚ Zn-Asp964: 45.3%; ionic; 1.82 A˚
Zn-Asp870: 86.8%; ionic; 2.35 A˚ Zn2+: 100.0%; ionic; 1.97 A˚
Zn-His872: 35.0%; ionic; 1.96 A˚
Zn-Asp964: 28.3%; ionic; 2.46 A˚
Zn2+: 100.0%; ionic; 2.46 A˚
Equilibration – heating 10 ps Simulation 5000 ps – cooling 10 ps
Ala961: 12.6%; H-acc; 3.17 A˚ Gly831: 19.7%; H-donor; 1.79 A˚
His1006: 31.6%; H-acc; 2.83 A˚ Ser960: 18.6%; H-donor; 1.58 A˚
Zn-Asp870: 50.3%; ionic; 1.85 A˚ Gly831: 41.3%; H-acc; 2.85 A˚
Zn-Asp870: 41.8%; ionic; 1.80 A˚ Asn846: 33.0%; H-acc; 2.59 A˚
Zn-His872: 28.0%; ionic; 1.77 A˚ Ser960: 20.9%; H-acc; 3.09 A˚
Zn-Asp964: 11.1%; ionic; 1.73 A˚ Zn-Asp870: 19.6%; ionic; 2.18 A˚
Zn2+: 100.0%; ionic; 1.86 A˚ Zn-His872: 26.4%; ionic; 1.80 A˚
Zn-Asp964: 17.1%; ionic; 1.86 A˚
Zn2+: 100.0%; ionic; 2.18 A˚
HDAC6–O38 Before simulation (docking) Initialization 100 ps (300 K)
Ala10: 51.7%; H-acc; 2.82 A˚ Zn-His7: 21.3%; ionic; 1.72 A˚
Zn-His7: 62.4%; ionic; 1.98 A˚ Zn-Cys78: 15.1%; ionic; 2.04 A˚
Zn-Cys78: 11.6%; ionic; 2.38 A˚ Zn2+: 100.0%; ionic; 1.84 A˚
Zn2+: 100.0%; ionic; 2.18 A˚
Zn2+: 100.0%; ionic; 2.80 A˚
Equilibration – heating 10 ps Simulation 5000 ps – cooling 10 ps
Zn-His7: 33.6%; ionic; 1.78 A˚ His7: 45.3%; H-donor; 1.36 A˚
Zn-Cys78: 13.1%; ionic; 1.96 A˚ Zn-His7: 34.0%; ionic; 1.79 A˚
Zn2+: 100.0%; ionic; 1.84 A˚ Zn-Cys78: 88.7%; ionic; 2.51 A˚
Zn2+: 100.0%; ionic; 2.07 A˚
HDAC7–Kb17 Before simulation (docking) Initialization 100 ps (300 K)
His669: 36.3%; H-donor; 1.79 A˚ Asp707: 12.6%; H-donor; 2.19 A˚
Ser728: 59.0%; H-acc; 2.50 A˚ Leu729: 21.7%; H-acc; 2.99 A˚
Zn-Asp707: 93.9%; ionic; 2.27 A˚ Zn-Asp801: 12.1%; ionic; 1.92 A˚
Zn-Asp707: 86.9%; ionic; 2.04 A˚ Zn2+: 100.0%; ionic; 1.74 A˚
Zn-His709: 55.6%; ionic; 1.93 A˚
Zn-Asp801: 27.3%; ionic; 1.92 A˚
Zn2+: 100.0%; ionic; 2.60 A˚
Equilibration – heating 10 ps Simulation 5000 ps – cooling 10 ps
His670: 53.2%; H-acc; 2.60 A˚ Tyr726: 22.1%; H-donor; 2.88 A˚
Zn-Asp707: 92.8%; ionic; 2.10 A˚ Tyr726: 22.1%; H-acc; 2.88 A˚
Zn-Asp707: 88.1%; ionic; 2.06 A˚ Leu729: 29.3%; H-acc; 2.86 A˚
Zn-Asp801: 87.1%; ionic; 2.34 A˚ Zn-Asp707: 60.7%; ionic; 1.90 A˚
Zn-Asp801: 83.7%; ionic; 2.03 A˚ Zn-Asp707: 60.2%; ionic; 1.90 A˚
Zn2+: 100.0%; ionic; 2.07 A˚ Zn-His709: 23.5%; ionic; 1.72 A˚
Zn-Asp801: 13.8%; ionic; 1.73 A˚
Zn2+: 100.0%; ionic; 1.92 A˚
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Table 8 (continued)
Complex The best interactions between ligand and HDAC in molecular dynamics simulation
HDAC9–Gd40 Before simulation (docking) Initialization 100 ps (300 K)
Gly955: 66.0%; H-acc; 2.69 A˚ Zn-Asp820: 85.2%; ionic; 2.03 A˚
Zn-Asp820: 59.6%; ionic; 2.12 A˚ Zn-Asp820: 80.7%; ionic; 2.01 A˚
Zn-His822: 10.1%; ionic; 3.15 A˚ Zn-Asp914: 48.5%; ionic; 2.04 A˚
Zn-Asp914: 39.0%; ionic; 1.87 A˚ Zn2+: 100.0%; ionic; 2.09 A˚
Zn-Asp914: 10.7%; ionic; 3.06 A˚
Zn2+: 100.0%; ionic; 2.42 A˚
Equilibration – heating 10 ps Simulation 5000 ps – cooling 10 ps
His782: 20.5%; H-acc; 2.77 A˚ Gly955: 66.0%; H-acc; 2.69 A˚
Zn-Asp820: 94.2%; ionic; 2.10 A˚ Zn-Asp820: 59.6%; ionic; 2.12 A˚
Zn-Asp820: 77.0%; ionic; 1.98 A˚ Zn-His822: 10.1%; ionic; 3.15 A˚
Zn-Asp914: 17.1%; ionic; 1.90 A˚ Zn-Asp914: 39.0%; ionic; 1.87 A˚
Zn2+: 100.0%; ionic; 2.06 A˚ Zn-Asp914: 10.7%; ionic; 3.06 A˚
Zn2+: 100.0%; ionic; 2.42 A˚
HDAC10–Aa50 Before simulation (docking) Initialization 100 ps (300 K)
Zn-Asp172: 79.5%; ionic; 2.03 A˚ Zn-Asp172: 68.5%; ionic; 1.94 A˚
Zn-Asp172: 31.9%; ionic; 2.63 A˚ Zn-Asp172: 54.6%; ionic; 1.87 A˚
Zn-His174: 11.7%; ionic; 2.92 A˚ Zn-His174: 30.2%; ionic; 1.78 A˚
Zn-Asp265: 21.6%; ionic; 1.89 A˚ Zn2+: 100.0%; ionic; 1.89 A˚
Zn2+: 100.0%; ionic; 2.22 A˚
Equilibration – heating 10 ps Simulation 5000 ps – cooling 10 ps
Zn-Asp172: 13.3%; ionic; 1.75 A˚ Zn-Asp172: 78.3%; ionic; 2.00 A˚
Zn-His174: 23.2%; ionic; 1.76 A˚ Zn-Asp172: 62.3%; ionic; 2.47 A˚
Zn2+: 100.0%; ionic; 1.90 A˚ Zn-His174: 40.0%; ionic; 1.95 A˚
Zn-Asp265: 20.4%; ionic; 1.92 A˚
Zn2+: 100.0%; ionic; 2.25 A˚
a This interaction data represent contact residues, percentage, type and length of interaction. Red color indicated the catalytic site. H-acc and
H-donor indicate the hydrogen acceptor and donor respectively.
In silico identiﬁcation of 2-oxo-1,3-thiazolidine derivatives 15changes of a-helix, b-sheet and loop conformation as protein
domains (Levinson et al., 2006). During folding and unfolding
process, the stability of the enzyme-inhibitor complex also
changes to include inhibitor interaction with enzyme active
site. Molecular dynamics simulation then aims to evaluate this
change.
The selected best ligands to undergo this simulation accord-
ing to the drug screening result were F with HDAC4, Ib14 with
HDAC5, O38 with HDAC6, Kb17 with HDAC7, Gd40 with
HDAC9, and Aa50 with HDAC10. Simulation was done at
pico to nanoseconds time scale (1012–109 s) as domain pro-
tein changes could be observed at this range. First, initialization
time was calculated to determine the complex conformational
energy and time needed for stability in the presence of implicit
solvent. It is run for 100 ps at 300 K. At the end of the simula-
tion, the entire ligands still interact with the enzyme.
MD simulation was then continued for 5000 ps. The heat-
ing for 10 ps from 300 K to 310 K was performed ﬁrst and
ended with cooling for 10 ps until 1 K. At the end of the sim-
ulation, all complexes were allowed to remain stable and all
best ligands were still strongly interacted with the enzyme.
The complex stability could be evaluated from RMSD (root
mean square deviation) value along the simulation. The
RMSD curve of all complexes is presented in Fig. 7. We can
see in Fig. 7 that all complexes are stable in respective
RMSD value. However, we took ligand interaction between
HDAC4-F as a simulation proxy, as it is having the most
stable RMSD value, and re-run the dynamics simulation for
20,000 ps. As shown in Fig. 8, the dynamics simulation isPlease cite this article in press as: Tambunan, U.S.F. et al., In silico identiﬁcation of
deacetylase (HDAC) in cervical cancer treatment. Arabian Journal of Chemistry (20beginning to retain its stability starting at 4000 ps. Hence,
the Ramachandran plot at Fig. 9 shows that the residues of
the enzyme are still within the 15% threshold in the disallowed
region.
Additionally, all best ligands also tend to have a better
interaction with HDACs after molecular dynamics simulation
takes place. The interaction data of the best ligands with cor-
responding HDACs in each MD simulation stage are pre-
sented in Table 8. According to these results it could be
concluded that best ligand inhibitors have a strong interaction
with enzyme. Consequently, the formed complexes remained
stable despite being inﬂuenced by solvent.4. Conclusion
In this study, novel potential inhibitors for cervical cancer tar-
geting H. sapiens class II histone deacetylase (HDAC) were
designed by de novo approach. Based on pharmacophore
model, HDAC inhibitors (HDACIs) consist of three main
parts: zinc binding group (ZBG), linker and hydrophobic
cap (CAP). From this model, the compound series based
on 4-[(2-oxo-1,3-thiazolidin-3-yl)carbonyl]aniline has been
designed and modiﬁed. In silico studies have been performed
for testing pharmacological properties and bioactivities of
designed ligands.
The best ligands selection from molecular docking simula-
tion was based on free energy of binding (DGbinding) and
molecular interaction with enzyme active site. The selection2-oxo-1,3-thiazolidine derivatives as novel inhibitor candidate of class II histone
15), http://dx.doi.org/10.1016/j.arabjc.2015.07.010
16 U.S.F. Tambunan et al.yielded eight best ligands which have better binding afﬁnity
(lower free energy of binding) than SAHA, TSA, and VPA
standards. Through interaction analysis of enzyme–ligand
complex, all best ligands have interactions which followed
hypothesis. Fragment 2-oxo-1,3-thiazolidine as zinc binding
group (ZBG) forms a covalent coordination bond with the
Zn2+ cofactor in HDAC charge-relay system with interaction
that reached 100.0%.
Pharmacology analysis was then performed to assess bioac-
tivity and pharmacological properties. All eight best ligands
meet Lipinski’s rule of ﬁve and have drug likeness and drug
score higher than standards. They also have a lower solubility
in water than standards. Hence, it could be concluded that the
best ligands are not easily excreted to enhance their bioactivity.
In silico preclinical trial was also conducted to evaluate the
ADMET properties of the ligands including toxicological
properties, passive absorption, health effect probability,
MRDD prediction and oral bioavailability prediction. Based
on the results, on average, all best ligands have a low toxicity
and health effect probability on blood, cardiovascular system,
gastrointestinal system, kidney, liver and lugs. They also have
a high passive absorption and good oral bioavailability based
on Veber’s and Egan’s rules.
Molecular dynamics (MD) simulations were also conducted
to predict the stability of enzyme–ligand complexes on solvent
effects. Based on this simulation, complexes formed by HDAC
and corresponding best ligands have a good stability. All best
ligands still strongly interacted with HDAC, mainly fragment
2-oxo-1,3-thiazolidine as zinc binding group (ZBG). The entire
ligands also have a good synthetic accessibility predicted by
CAESA. It could be inferred through these assessments that
all designed ligands are potential to be novel HDAC inhibitors
(HDACIs) and cervical cancer drug leads.
From the drug screening based on docking, dynamics and
drug scan analysis, the best inhibitor ligands for HDAC4,
HDAC5, HDAC6, HDAC7, HDAC9, and HDAC10 are F,
Ib14, O38, Kb17, Gd40, and Aa50 respectively. The best
ligands from drug screening then could be developed as novel
potent drugs for cervical cancer targeting H. sapiens class II
histone deacetylase (HDAC).
It can be deduced that the combination of in silico drug
design based on de novo lead molecules design approach,
molecular docking, pharmacology analysis, virtual screening,
and manual interpretation can be more efﬁcient to discover
new effective inhibitors and drug leads that may have a great
impact for future experimental studies. Computational or in
silico methods play the important roles in drug discovery
and development and can improve the efﬁciency of the novel
HDACIs. This method may limit the use of chemicals for syn-
thesis and biological testing, thus greatly reducing resource
requirements than conventional methods. This study is
expected to produce more potent HDAC inhibitors as drugs
for cervical cancer treatment.
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